Audrey Swiader
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Audrey Swiader has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandr Kalmykov
GeneXplain GmbH, Wolfenbuettel, Germany
1 shared publication - Alexander Kel
GeneXplain GmbH, Germany
1 shared publication - Amandine Wahart
I2MC, Université de Toulouse, Institut National de la Santé et de la Recherche Médical U1297, Université Toulouse III-Paul Sabatier (UPS), France
1 shared publication - Charlotte Rouzaud Laborde
National Institute of Health and Medical Research (INSERM) U1297–University of Toulouse, 31432 Toulouse Cedex 4, France
1 shared publication Cormier Kévin
I2MC, Université de Toulouse, Institut National de la Santé et de la Recherche Médical U1297, Université Toulouse III-Paul Sabatier (UPS), France
1 shared publication- Damien Ramel
Department of Vascular Biology of the Institute of Metabolic and Cardiovascular Diseases (I2MC), Université de Toulouse 3, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1048, Toulouse, France
1 shared publication
Latest Publications
- Open Access
- 15 August 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (33) , eadx0968
Transcriptome fingerprinting of aberrant fibroblast activation unlocks effective therapeutics to tackle cardiac fibrosis
Aberrant activation of fibroblasts is a pivotal component of cardiac fibrosis predisposing to heart failure. However, the molecular regulation of the functional state of cardiac fibroblasts in fibrosis resolution remains largely unexplored, and therefore, effective antifibrosis therapies are still lacking. By translating mouse transcriptomics to humans, we unlocked common molecular denominators connecting the fibroblast phenotypic state and fibrogenic signaling pathways in cardiac fibrosis. Through the construction of a fibroblast-specific transcriptional gene regulatory network, we found ITGAL and DUSP9 as key druggable targets for human myocardial fibrosis. A computational drug repurposing approach predicted 367 antifibrotic candidate compounds for heart disease. In primary cardiac fibroblasts derived from patients with heart failure, we provided experimental validation of the top 2–ranked repositioned drug candidates and their combination. These innovative approaches facilitate the identification of potential targets and drug candidates for cardiac fibrosis, providing actionable opportunities for clinical translation.
- 15 August 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (33) , eadx0968
Open AccessTranscriptome fingerprinting of aberrant fibroblast activation unlocks effective therapeutics to tackle cardiac fibrosis
Aberrant activation of fibroblasts is a pivotal component of cardiac fibrosis predisposing to heart failure. However, the molecular regulation of the functional state of cardiac fibroblasts in fibrosis resolution remains largely unexplored, and therefore, effective antifibrosis therapies are still lacking. By translating mouse transcriptomics to humans, we unlocked common molecular denominators connecting the fibroblast phenotypic state and fibrogenic signaling pathways in cardiac fibrosis. Through the construction of a fibroblast-specific transcriptional gene regulatory network, we found ITGAL and DUSP9 as key druggable targets for human myocardial fibrosis. A computational drug repurposing approach predicted 367 antifibrotic candidate compounds for heart disease. In primary cardiac fibroblasts derived from patients with heart failure, we provided experimental validation of the top 2–ranked repositioned drug candidates and their combination. These innovative approaches facilitate the identification of potential targets and drug candidates for cardiac fibrosis, providing actionable opportunities for clinical translation.
- Open Access
Hyperglycemia worsens smooth muscle foam cell formation through PI3Kγ-dependent defective autophagy
Background: Diabetes significantly increases the risk of cardiovascular complications, particularly through the mechanisms of atherosclerosis. In this context, uncontrolled hyperglycaemia is a key contributor to arterial dysfunctions. However, the specific effects of elevated glucose levels on smooth muscle cells (SMC)-derived foam cells formation remain poorly defined. Methods: Using a wire injury-based accelerated atherosclerosis mouse model combined to lipid biochemistry and cellular lipid imaging approaches, we analysed molecular mechanisms involved in SMC derived foam cell formation. Results: Our findings demonstrated that hyperglycaemia induced a specific lipid loading in SMC in an accelerated atherosclerosis mice model. In vitro , high glucose concentration negatively affected autophagic process independently of lipid uptake and efflux in human and mouse primary SMC. Consistently, treatment with autophagy activators successfully reduced lipid droplet formation. Mechanistically, we identified that PI3Kψ activity impaired autophagy through TFEB phosphorylation promoting SMC foam cells formation in response to high glucose. Conclusion: These findings shed light on the mechanisms underlying SMC homeostasis disruption under hyperglycemic conditions and underscore the potential therapeutic window for PI3Kψ inhibitor in managing cardiovascular diseases in diabetic patients.
Open AccessHyperglycemia worsens smooth muscle foam cell formation through PI3Kγ-dependent defective autophagy
Background: Diabetes significantly increases the risk of cardiovascular complications, particularly through the mechanisms of atherosclerosis. In this context, uncontrolled hyperglycaemia is a key contributor to arterial dysfunctions. However, the specific effects of elevated glucose levels on smooth muscle cells (SMC)-derived foam cells formation remain poorly defined. Methods: Using a wire injury-based accelerated atherosclerosis mouse model combined to lipid biochemistry and cellular lipid imaging approaches, we analysed molecular mechanisms involved in SMC derived foam cell formation. Results: Our findings demonstrated that hyperglycaemia induced a specific lipid loading in SMC in an accelerated atherosclerosis mice model. In vitro , high glucose concentration negatively affected autophagic process independently of lipid uptake and efflux in human and mouse primary SMC. Consistently, treatment with autophagy activators successfully reduced lipid droplet formation. Mechanistically, we identified that PI3Kψ activity impaired autophagy through TFEB phosphorylation promoting SMC foam cells formation in response to high glucose. Conclusion: These findings shed light on the mechanisms underlying SMC homeostasis disruption under hyperglycemic conditions and underscore the potential therapeutic window for PI3Kψ inhibitor in managing cardiovascular diseases in diabetic patients.